Informations générales (source: ClinicalTrials.gov)
Microparticles as a Biomarker of Incident Cardiovascular Risk in Patients With Obstructive Sleep Apnea
Observational
University Hospital, Angers (Voir sur ClinicalTrials)
février 2018
février 2026
28 août 2025
Obstructive sleep apnea (OSA) is independently associated with cardiovascular diseases,
including myocardial infarction and stroke. OSA may promote atherosclerosis risk factors
such as hypertension, diabetes and dyslipidemia and may have direct proatherogenic
effects on the vascular wall. A growing number of studies have recently focused on the
role of microparticles (MPs) in the atherogenic process. Case-control studies have shown
that platelet-, endothelial- and leukocyte-derived MP levels are increased in OSA and
that leukocyte-derived MP are released during the night in OSA. Furthermore, experimental
evidence shows that MPs from OSA patients induce endothelial dysfunction.
The objective of this prospective study is to evaluate the impact of increased levels of
leukocyte derived MPs on the cardiovascular outcomes in patients with prevalent
cardiovascular diseases investigated for OSA.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Laboratoire du Sommeil, Département de Pneumologie, CHU d'Angers - 49100 - Angers - France | Wojciech Trzepizur, MD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- diagnosis of coronary artery disease or cerebrovascular disease
- diagnosis of moderate-to-severe OSA
- diagnosis of coronary artery disease or cerebrovascular disease
- diagnosis of moderate-to-severe OSA
- pregnancy
- previously treated OSA